The role of probiotics and antibiotics in regulating mucosal inflammation

Advances in Experimental Medicine and Biology

Volumn 579, Issue , 2006, Pages 219-226

  Duchmann, Rainer ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; PROBIOTICS;

EID: 37649001157     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-33778-4_14     Document Type: Review

References (74)

1. Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989; 66(5):365-78.
2. Gibson G, Roberfroid M. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotcs. J Nutr 1995; 125(6):1401-1412.
3. Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: Approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999; 69(5):1052S-1057S.
4. Gibson GR, Fuller R. Aspects of in vitro and in vivo research approaches directed toward identifying probiotics and prebiotics for human use. J Nutr 2000; 130(2S Suppl):391S-395S.
5. Hart AL, Stagg AJ, Frame M et al. The role of the gut flora in health and disease, and its modification as therapy. Aliment Pharmacol Ther 2002; 16(8):1383-93.
6. Hart AL, Stagg AJ, Kamm MA. Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2003; 36(2):111-9.
7. Schultz M, Sartor RB. Probiotics and inflammatory bowel diseases. Am J Gastroenterol 2000; 95(1 Suppl):S19-21.
8. Szajewska H, Kotowska M, Mrukowicz J et al. Efficacy of lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001; 138(3):361-365.
9. Isolauri E, Juntunen M, Rautanen T et al. A human lactobacillus strain promotes recovery from acute diarrhea in children. Pediatrics 1991; 88(1):90-97.
10. Kalliomaeki M, Salminen S, Arvilommi H et al. Probiotcs in primary prevention of atopic disease: A randomised placebo-controlled trail. Lancet 2001; 357:1076-1079.
11. Fabia R, Ar'Rajab A, Johansson ML et al. The effect of exogenous administration of lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. Scand J Gastroenterol 1993; 28(2):155-62.
12. Mao Y, Nobaek S, Kasravi B et al. The effects of lactobacillus strains and oat fiber on methotrexate- induced enterocolitis in rats. Gastroenterology 1996; 111(2):334-44.
13. Madsen K, Doyle J, Jewell L et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116(5):1107-1114.
14. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25(4):653-8.
15. Kruis W, Schutz E, Fric P et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11(5):853-8.
16. Rembacken BJ, Snelling AM, Hawkey PM et al. Nonpathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 1999; 354(9179):635-9.
17. Kruis W, Fric P, Stolte M. Maintenence of remission in ulcerative colitis is equally effective with Escherichia coli nissle 1917 and with standard mesalamine. Gastroenterology 2001; 120(5):A127.
18. Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double blind, placebo-conroled trial. Gastroenterology 2000; 119(2):305-9.
19. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. Z Gastroenterol 1993; 31(2):129-34.
20. Guslandi M, Mezzi G, Sorghi M et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45(7):1462-4.
21. McFarland LV, Surawicz CM, Greenberg RN et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995; 90(3):439-48.
22. McFarland LV, Surawicz CM, Greenberg RN et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. Jama 1994; 271(24):1913-8.
23. Flynn S, van Sinderen D, Thornton GM et al. Characterization of the genetic locus responsible for the production of ABP-118, a novel bacteriocin produced by the probiotic bacterium Lactobacillus salivarius subsp. salivarius UCC118. Microbiology 2002; 148(Pt 4):973-84.
24. Madsen K, Cornish A, Soper P et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121(3):580-91.
25. Cario E, Rosenberg IM, Brandwein SL et al. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol 2000; 164(2):966-72.
26. Neutra M, Mantis N, Kraehenbuhl J. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol 2001; 2(11):1004-1009.
27. Rescigno, Urbano M, Valzasina B et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001; 2(4):288-290.
28. O'Boyle C, MacFie J, Mitchell C et al. Microbiology of bacterial translocation in humans. Gut 1998; 42(1):29-35.
29. McCall R, Haskill J, Zimmermann E et al. Tissue interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology 1994; 106:960-972.
30. Schwab J. Phlogisic properties of peptidoglycan-polysaccharide polymers from cell walls of pathogenic and normal-flora bacteria which colonize humans. Infect Immun 1993; 61:4535-4539.
31. Mowat A, Weiner H. Oral tolerance. Physiological Basis and Clinical Applications. Mucosal Immunology. 2nd ed. In: Orgra PL, Mestecky J, Lamm ME et al, eds. Academic Press, 1999:587-618.
32. Haller D, Bode C, Hammes WP et al. Nonpathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte cocultures. Gut 2000; 47(1):79-87.
33. Khoo UY, Proctor IE, Macpherson AJ. CD4+ T cell down-regulation in human intestinal mucosa: Evidence for intestinal tolerance to luminal bacterial antigens. J Immunol 1997; 158(8):3626-34.
34. Kullberg MC, Jankovic D, Gorelick PL et al. Bacteria-triggered CD4(+) T regulatory cells suppress Helicobacter hepaticus-induced colitis. J Exp Med 2002; 196(4):505-15.
35. Neish A, Gewirtz A, Zeng H et al. Prokaryotic regulation of epithelial responses by inhibition of IkB-alpha ubiquitination. Science 2000; 289:1560-1563.
36. Zhang G, Ghosh S. Toll-like receptor-mediated NF-kappaB activation: A phylogenetically conserved paradigm in innate immunity. J Clin Invest 2001; 107(1):13-9.
37. Girardin SE, Tournebize R, Mavris M et al. CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive shigella flexneri. EMBO Rep 2001; 2(8):736-42.
38. Medzhitov R, Janeway Jr C. Innate immunity. N Engl J Med 2000; 343(5):338-44.
39. Duchmann R, Neurath MF, Meyer zum Buschenfelde KH. Responses to self and nonself intestinal microflora in health and inflammatory bowel disease. Res Immunol 1997; 148(8-9):589-94.
40. Duchmann R, Kaiser I, Hermann E et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol 1995; 102(3):448-455.
41. Duchmann R, Schmitt E, Knolle P et al. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996; 26:934-938.
42. Videla S, Vilaseca J, Guarner F et al. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 1994; 35(8):1090-7.
43. Rath HC, Schultz M, Freitag R et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69(4):2277-85.
44. Madsen KL, Doyle JS, Tavernini MM et al. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology 2000; 118(6):1094-105.
45. Moss A, Carbone J, Kressel H. Radiologic and clinical assessment of broad-spectrum antibiotic therapy in Crohn's disease. Am J Roentgenol 1978; 131(5):787-790.
46. Sutherland L, Singleton J, Sessions J et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32(9):1071-5.
47. Ursing B, Alm T, Barany F et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982; 83(3):550-62.
48. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000; 118(2 Suppl 1):S68-82.
49. Zeitz M. Guidelines of the DGVS. Pouchitis. German Society of Digestive and Metabolic Diseases. Z Gastroenterol 2001; 39(1):59-62.
50. Roche Y, Gougerot-Pocidalo MA, Fay M et al. Comparative effects of quinolones on human mononuclear leucocyte functions. J Antimicrob Chemother 1987; 19(6):781-90.
51. Grove DI, Mahmound AA, Warren KS. Suppression of cell-mediated immunity by metronidazole. Int Arch Allergy Appl Immunol 1977; 54(5):422-7.
52. Rath H, Ikeda J, Wilson K et al. Cecal bacterial loads influence colitis and gastritis in HLA B27 transgenic rats. Gastroenterology 1997; 112:A1068.
53. Rath HC, Herfarth HH, Ikeda JS et al. Normal luminal bacteria, especially bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98(4):945-53.
54. Darfeuille-Michaud A, Neut C, Barnich N et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998; 115(6):1405-13.
55. Masseret E, Boudeau J, Colombel JF et al. Genetically related Escherichia coli strains associated with Crohn's disease. Gut 2001; 48(3):320-5.
56. Boudeau J, Glasser AL, Masseret E et al. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect Immun 1999; 67(9):4499-509.
57. Boudeau J, Barnich N, Darfeuille-Michaud A. Type 1 pili-mediated adherence of Escherichia coli strain LF82 isolated from Crohn's disease is involved in bacterial invasion of intestinal epithelial cells. Mol Microbiol 2001; 39(5):1272-84.
58. Glasser AL, Boudeau J, Barnich N et al. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001; 69(9):5529-37.
59. Swidsinski A, Ladhoff A, Pernthaler A et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122(1):44-54.
60. Duchmann R, Marker-Hermann E, Meyer zum Buschenfelde KH. Bacteria-specific T-cell clones are selective in their reactivity towards different enterobacteria or H. pylori and increased in inflammatory bowel disease. Scand J Immunol 1996; 44(1):71-9.
61. Duchmann R, May E, Heike M et al. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut 1999; 44(6):812-8.
62. Duchmann R. The role of resident intestinal bacteria. Chronic inflammatory bowel diseases. Progress and Controversies. In: Holoman J, Glasa J, eds. Progress in Hepato-Pharmacology, 2000; 5:17-31.
63. Foo MC, Lee A. Antigenic cross-reaction between mouse intestine and a member of the autochthonous microflora. Infect Immun 1974; 9(6):1066-9.
64. Foo MC, Lee A. Immunological response of mice to members of the autochthonous intestinal microflora. Infect Immun 1972; 6(4):525-32.
65. Moore WE, Burmeister JA, Brooks CN et al. Investigation of the influences of puberty, genetics, and environment on the composition of subgingival periodontal floras. Infect Immun 1993; 61(7):2891-8.
66. Van de Merwe JP, Stegeman JH, Hazenberg MP. The resident faecal flora is determined by genetic characteristics of the host. Implications for Crohn's disease? Antonie Van Leeuwenhoek 1983; 49(2):119-24.
67. Wilson K, Blitchington R. Human colonic biota studied by ribosoal DNA sequence analysis. Appl Environ Microbiol 1996; 62(7):2273-227.
68. Hooper LV, Wong MH, Thelin A et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001; 291(5505):881-4.
69. Steidler L, Hans W, Schotte L et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin- 10. Science 2000; 289(5483):1352-5.
70. Matsui K, Nagano K, Arai T et al. DNA sequencing of the gene encoding Salmonella typhimurium-derived T- cell inhibitor (STI) and characterization of the gene product, cloned STI. FEMS Immunol Med Microbiol 1998; 22(4):341-9.
71. Klapproth JM, Scaletsky IC, McNamara BP et al. A large toxin from pathogenic Escherichia coli strains that inhibits lymphocyte activation. Infect Immun 2000; 68(4):2148-55.
72. Darji A, Guzman CA, Gerstel B et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997; 91(6):765-75.
73. Fennelly GJ, Khan SA, Abadi MA et al. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J Immunol 1999; 162(3):1603-10.
74. Paglia P, Medina E, Arioli I et al. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 1998; 92(9):3172-6.